NAPLEX Quiz: Controlled Substances

What this quiz covers

This quiz focuses on Controlled Substances, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Recommend non-opioid analgesics first and contact the prescriber to avoid tramadol due to additive central nervous system depression with clonazepam and zolpidem (correct answer)
2. Dispense tramadol as written and instruct the patient to double zolpidem on nights with more pain to improve sleep
3. Switch tramadol to meperidine 50 mg by mouth every 4 hours as needed because it has less interaction with benzodiazepines
4. Dispense tramadol as written and recommend urine drug screening every 24 hours while taking tramadol

Explanation: This question evaluates the recognition of dangerous drug interactions with controlled substances in the setting of acute pain management. The critical patient-specific factor is the concurrent use of two CNS depressants (clonazepam and zolpidem) with a proposed third CNS depressant (tramadol), creating significant risk for respiratory depression and sedation. Option A is correct because it prioritizes non-opioid alternatives and recognizes the serious interaction potential between tramadol and the existing benzodiazepine/Z-drug combination. Option B is dangerously incorrect as it not only ignores the interaction but suggests doubling the zolpidem dose, which could be fatal. Option C is wrong because meperidine has even more concerning interactions and toxicity risks, especially with serotonergic medications like sertraline. Option D inappropriately suggests excessive monitoring without addressing the core safety issue. The clinical framework is that combining multiple CNS depressants significantly increases overdose risk, and alternative pain management strategies should be explored first, especially for acute dental pain which typically responds well to NSAIDs and acetaminophen.

Question 2

1. Stop lorazepam abruptly today to avoid fetal exposure, without tapering
2. Recommend a gradual taper to reduce withdrawal risk and coordinate with prescriber/OB provider; emphasize nonpharmacologic sleep strategies during pregnancy (correct answer)
3. Increase lorazepam to 2 mg nightly to reduce pregnancy-related anxiety and improve sleep
4. Switch to diazepam 10 mg nightly immediately because it is safer in pregnancy than lorazepam

Explanation: This question evaluates the management of benzodiazepine discontinuation in pregnancy, focusing on withdrawal risks and fetal safety for Schedule IV controlled substances like lorazepam. The key patient-specific factor is the patient's 6-month use of lorazepam for insomnia, now complicated by early pregnancy, where abrupt cessation could cause maternal withdrawal symptoms harmful to both mother and fetus. Recommending a gradual taper in coordination with the prescriber and OB provider is the best choice as it minimizes withdrawal risks while incorporating nonpharmacologic strategies to support sleep during pregnancy. Abruptly stopping lorazepam is suboptimal due to high withdrawal risk, increasing the dose could heighten fetal exposure and dependence, and switching to diazepam is not safer given its longer half-life and potential for accumulation in pregnancy. A common misconception in controlled substance management is that all benzodiazepines are interchangeable or that pregnancy necessitates immediate cessation without tapering, ignoring withdrawal dangers. A transferable pearl is to use validated tools like the Clinical Institute Withdrawal Assessment for Benzodiazepines when tapering. Guidelines emphasize shared decision-making, risk-benefit assessment, and monitoring for misuse in pregnant patients on controlled substances.

Question 3

1. Recommend a gradual taper/discontinuation plan and nonpharmacologic insomnia strategies; contact prescriber to reassess therapy rather than escalating zolpidem dose (correct answer)
2. Recommend increasing zolpidem to 20 mg nightly indefinitely because tolerance is expected
3. Add alprazolam (Schedule IV) 1 mg nightly to improve sleep while continuing zolpidem
4. Advise taking zolpidem with 2 glasses of wine to enhance hypnotic effect

Explanation: This question assesses the management of tolerance and dependence in long-term non-benzodiazepine hypnotic use for insomnia. The key patient-specific factor is the patient's self-escalation to double zolpidem doses, indicating potential dependence alongside venlafaxine, which may worsen insomnia if not addressed. Option A is the best choice as recommending a gradual taper with nonpharmacologic strategies and prescriber reassessment prevents withdrawal while avoiding escalation. Option B is incorrect because indefinite increases risk adverse effects, a misconception that tolerance justifies higher doses. Option C is suboptimal as adding alprazolam compounds sedation; option D dangerously enhances effects with alcohol. A pearl is that zolpidem is recommended for short-term use per AASM guidelines. Use a deprescribing framework incorporating cognitive behavioral therapy for insomnia in controlled substance management.

Question 4

1. Fill the prescription because Schedule II medications do not require prescriber DEA number on the prescription
2. Refuse to fill and immediately destroy the prescription without documenting because it is incomplete
3. Hold dispensing and contact the prescriber to verify and obtain missing required information; document due diligence and check PDMP before deciding to dispense (correct answer)
4. Change the quantity to 30 tablets and dispense without contacting the prescriber to reduce risk

Explanation: This question assesses the verification process for incomplete or suspicious Schedule II prescriptions to prevent diversion. The key patient-specific factors include the missing DEA number and patient address, cash payment, refusal of ID, and history of heroin use disorder, raising red flags for legitimacy. Option C is the best choice as holding, contacting the prescriber for missing information, documenting, and checking PDMP ensures compliance with DEA requirements before dispensing. Option A is incorrect because Schedule II prescriptions must include DEA numbers, a regulatory misconception. Option B is suboptimal as destroying without documentation violates protocols; option D involves unauthorized changes, risking legal issues. A clinical pearl is that pharmacists have 'corresponding responsibility' to resolve red flags per 21 CFR 1306.04. Implement a decision framework using PDMP and prescriber verification for all suspicious controlled substance prescriptions.

Question 5

1. Dispense clarithromycin and methadone without intervention because antibiotics do not interact with opioids
2. Contact prescribers to avoid or change clarithromycin due to increased methadone levels and QT prolongation risk; recommend correcting electrolytes and consider electrocardiogram monitoring (correct answer)
3. Increase methadone dose during clarithromycin therapy to prevent withdrawal
4. Monitor QT interval once yearly only, regardless of interacting medications or electrolyte abnormalities

Explanation: This question tests the management of drug interactions between methadone and macrolides in patients with cardiac risk factors. The key patient-specific factors are clarithromycin's potential to increase methadone levels and prolong QT interval, exacerbated by hypokalemia, hypomagnesemia, and heart failure. Option B is the best choice as contacting prescribers to avoid clarithromycin, correct electrolytes, and consider ECG monitoring prevents torsades de pointes and overdose. Option A is incorrect because antibiotics like clarithromycin do interact via CYP3A4 inhibition, a common oversight. Option C is suboptimal as increasing methadone risks toxicity; option D underestimates acute risks with insufficient monitoring. A pearl is that methadone requires QT monitoring per FDA black box warnings when combined with QT-prolonging drugs. Use a framework assessing electrolyte status and ECG needs for high-risk opioid interactions.

Question 6

1. Fill the new prescription immediately and instruct the patient to discard the previous supply
2. Decline to fill and contact the prescriber to verify the dose change and timing; document and assess for early refill/escalation concerns using PDMP data (correct answer)
3. Fill both prescriptions and counsel to alternate doses every other day
4. Change the medication to lisdexamfetamine 70 mg daily without prescriber authorization

Explanation: This question evaluates the handling of potential dose escalation or early refills for stimulants in young adults. The key patient-specific factors are the recent fill of a lower dose and the quick escalation to 30 mg without clear rationale, per PDMP, raising concerns for misuse or diversion. Option B is the best choice as declining to fill immediately, contacting the prescriber for verification, and documenting with PDMP assessment prevents inappropriate escalation and ensures therapeutic legitimacy. Option A is incorrect because dispensing without verification risks enabling abuse, a misconception in rapid dose changes. Option C is suboptimal as filling both promotes overuse; option D involves unauthorized substitution. A clinical pearl is that stimulant doses should be titrated gradually per APA ADHD guidelines. Apply a decision framework reviewing PDMP for patterns before approving controlled substance dose changes.

Question 7

1. Ignore the urine drug test results and continue dispensing opioids as long as the prescription is valid
2. Contact the prescriber to discuss the unexpected urine drug test findings and coordinate next steps (confirmatory testing, reassessment of therapy, and risk mitigation) before dispensing (correct answer)
3. Increase oxycodone dose because a negative test proves the patient metabolizes oxycodone rapidly
4. Advise the patient to take extra oxycodone before the next urine test so it will be positive

Explanation: This question tests the response to unexpected urine drug test results in opioid therapy monitoring. The key patient-specific factors are the negative oxycodone and positive benzodiazepine results, unexplained in a patient with stimulant use disorder history, suggesting possible nonadherence or diversion. Option B is the best choice as contacting the prescriber for discussion, confirmatory testing, and therapy reassessment ensures accurate interpretation and safe continuation before dispensing. Option A is incorrect because ignoring results neglects risk mitigation, a misconception that valid prescriptions override monitoring. Option C is suboptimal as assuming rapid metabolism lacks evidence; option D promotes manipulation of tests. A clinical pearl is that UDTs should include confirmatory testing for unexpected results per CDC guidelines. Employ a framework interpreting UDTs with patient history and PDMP for controlled substance stewardship.

Question 8

1. Dispense the prescription as written because Schedule II prescriptions do not require the prescriber's DEA number if handwritten
2. Refuse to dispense and destroy the prescription because any missing element makes it invalid and non-correctable
3. Contact the prescriber to verify and obtain required information (including DEA number) and assess appropriateness before dispensing (correct answer)
4. Change the dose to 10 mg three times daily based on the prior fill and dispense without contacting the prescriber

Explanation: This question tests knowledge of Schedule II prescription requirements and appropriate pharmacist response to incomplete prescriptions. The critical issue is a Schedule II prescription missing the prescriber's DEA number, which is a federal requirement for all controlled substance prescriptions. Option C is correct because federal law requires specific elements on Schedule II prescriptions including the prescriber's DEA number, and while some elements can be added after verbal verification, the pharmacist must contact the prescriber to obtain missing information and verify the prescription's legitimacy. Option A is incorrect because all Schedule II prescriptions require a DEA number regardless of whether they are handwritten or electronic. Option B is wrong because missing information can often be corrected through prescriber contact rather than destroying the prescription. Option D represents illegal prescription modification and bypasses necessary verification steps. The regulatory framework requires that Schedule II prescriptions contain all required elements including patient name, drug name/strength, quantity, directions, prescriber signature, and DEA number; missing elements must be verified with the prescriber before dispensing.

Question 9

1. Monitor for falls, confusion, and excessive sedation, especially during initiation and dose increases (correct answer)
2. Monitor absolute neutrophil count weekly for the first 6 months
3. Monitor international normalized ratio (INR) twice weekly due to increased bleeding risk
4. Monitor serum potassium daily due to risk of hyperkalemia from alprazolam

Explanation: This question addresses monitoring parameters for benzodiazepines in elderly patients with cognitive impairment. The key patient-specific factors are advanced age (67 years), mild cognitive impairment, and the recent initiation of a high-dose benzodiazepine regimen combined with another anticholinergic/sedating medication (diphenhydramine). Option A is correct because falls, confusion, and excessive sedation are the most critical safety concerns with benzodiazepines in elderly patients, particularly those with baseline cognitive impairment. Option B is incorrect as neutropenia is not a concern with alprazolam (this would be relevant for clozapine). Option C is wrong because alprazolam does not affect coagulation or INR. Option D is incorrect as alprazolam does not cause hyperkalemia. The clinical pearl is that benzodiazepines are potentially inappropriate medications in elderly patients (Beers Criteria) due to increased sensitivity and risk of falls, cognitive decline, and delirium, requiring close monitoring for these adverse effects rather than laboratory parameters.

Question 10

1. Continue the current opioid regimen and schedule urine drug screening every 12 months because he is on a stable dose
2. Dispense the refills as written and counsel only on constipation and safe storage because sedation is expected with opioids
3. Initiate an opioid taper by decreasing the total daily oxycodone dose by 50% every 2 days until discontinued
4. Assess overdose risk, provide naloxone, counsel to avoid other sedatives/alcohol, and recommend urgent evaluation and treatment of sleep apnea before escalating opioids (correct answer)

Explanation: This question tests the management of opioid therapy in a patient with multiple risk factors for respiratory depression. The key patient-specific factor is untreated obstructive sleep apnea combined with COPD and chronic opioid use, creating a dangerous combination for opioid-induced respiratory depression. Option D is the best choice because it addresses the immediate safety concerns by assessing overdose risk, providing naloxone for emergency reversal, counseling on avoiding additional CNS depressants, and recommending urgent treatment of sleep apnea before any opioid escalation. Option A is incorrect because continuing the current regimen without addressing the respiratory risks could be fatal. Option B fails to recognize the serious safety concerns and focuses only on minor side effects. Option C suggests an inappropriately rapid taper that could precipitate withdrawal and doesn't address the underlying sleep apnea. The clinical pearl is that untreated sleep apnea is a major risk factor for opioid-related mortality, and patients should have sleep disorders adequately treated before initiating or escalating opioid therapy.

Question 11

1. Recommend taking lisdexamfetamine at bedtime to reduce daytime palpitations and improve adherence
2. Contact the prescriber promptly to assess stimulant-related adverse effects and consider dose reduction or discontinuation; counsel to avoid other stimulants (caffeine/decongestants) until evaluated (correct answer)
3. Add pseudoephedrine 60 mg by mouth every 6 hours as needed to counteract fatigue from reduced sleep
4. Continue the current dose and monitor blood pressure once yearly because cardiovascular effects are usually transient

Explanation: This question addresses cardiovascular adverse effects of stimulant medications requiring urgent intervention. The key patient-specific factors are new-onset hypertension (152/92 mmHg), tachycardia (112 bpm), and cardiac symptoms (palpitations) after starting a moderate-high dose of lisdexamfetamine. Option B is correct because these cardiovascular effects require prompt medical evaluation and likely dose reduction or discontinuation of the stimulant, plus counseling to avoid other sympathomimetics that could worsen symptoms. Option A is dangerous as taking stimulants at bedtime would worsen insomnia without addressing cardiovascular risks. Option C is inappropriate and dangerous as adding another stimulant (pseudoephedrine) would exacerbate cardiovascular symptoms. Option D incorrectly minimizes serious cardiovascular effects that require immediate attention. The clinical framework emphasizes that stimulant-induced cardiovascular effects (hypertension, tachycardia, palpitations) require prompt evaluation and intervention, as they can progress to serious outcomes including myocardial infarction, stroke, or sudden death, particularly at higher doses.

Question 12

1. Respiratory rate and sedation level, especially during the first 24–72 hours after initiation or dose changes (correct answer)
2. International normalized ratio (INR) twice weekly
3. Serum potassium every 3 months
4. Absolute neutrophil count weekly

Explanation: This question tests the monitoring requirements for opioid therapy, particularly with transdermal fentanyl in cancer pain management. The key patient-specific factor is the initiation of fentanyl in an elderly patient with concurrent morphine use and constipation, increasing risks of respiratory depression and overdose. Option A is the best choice as monitoring respiratory rate and sedation, especially in the first 24–72 hours, allows early detection of life-threatening opioid-induced respiratory depression per FDA guidelines. Option B is incorrect because INR monitoring is irrelevant to opioids, a misconception confusing it with anticoagulant therapy. Option C is suboptimal as potassium checks are not primary for opioids; option D applies to neutropenia risks in chemotherapy, not opioids. A pearl is that fentanyl patches require peak effect monitoring around 24 hours post-application. Use a framework like the CDC's opioid checklist, emphasizing vital signs and sedation scales for high-risk controlled substance monitoring.

Question 13

1. Stop clonazepam abruptly today and continue escitalopram only
2. Implement a gradual taper (e.g., reduce total daily dose by 10%–25% every 1–2 weeks) with monitoring for withdrawal and anxiety recurrence, coordinating with the prescriber (correct answer)
3. Increase clonazepam to 2 mg three times daily to overcome tolerance and reduce sedation
4. Switch clonazepam to alprazolam 1 mg three times daily immediately without taper because both are benzodiazepines

Explanation: This question evaluates safe discontinuation strategies for long-term benzodiazepine use to prevent withdrawal. The key patient-specific factor is the high-dose, chronic clonazepam use for three years, which can lead to dependence and severe withdrawal symptoms like seizures if stopped abruptly. Option B is the best choice as implementing a gradual taper (10%–25% every 1–2 weeks) with monitoring minimizes withdrawal risks and allows anxiety reassessment in coordination with the prescriber. Option A is incorrect because abrupt cessation risks withdrawal syndrome, a common misconception that short-term use principles apply to chronic therapy. Option C is suboptimal as increasing the dose worsens sedation without addressing tolerance; option D provides no taper, risking equivalent withdrawal due to similar pharmacokinetics. A clinical pearl is that benzodiazepine tapers should be individualized, often using longer-acting agents like diazepam for smoother withdrawal. Apply a decision framework incorporating patient history and symptom monitoring to guide controlled substance deprescribing.

Question 14

1. Dispense linezolid and advise the patient to double the stimulant dose to counter fatigue from infection
2. Contact the prescriber because linezolid has monoamine oxidase inhibitor activity and may increase risk of hypertensive reaction with stimulants; consider alternative antibiotic or hold stimulant with monitoring (correct answer)
3. Dispense both medications and monitor blood pressure once after completing the 10-day antibiotic course
4. Switch the stimulant to methylphenidate without prescriber involvement because it has no interaction with linezolid

Explanation: This question tests the pharmacist's knowledge of drug interactions involving controlled substances, specifically the interaction between stimulants and antibiotics with monoamine oxidase inhibitor (MAOI) activity. The key patient-specific factor is the concurrent use of mixed amphetamine salts, a Schedule II stimulant, and linezolid, which exhibits weak MAOI activity, potentially leading to hypertensive crisis or serotonin syndrome. Contacting the prescriber is the best choice because it allows for evaluation of the interaction risk, consideration of alternative antibiotics, or temporary holding of the stimulant with appropriate monitoring to ensure patient safety. Dispensing linezolid while advising to double the stimulant dose is incorrect as it could exacerbate the interaction and is not evidence-based, while simply dispensing both with post-course blood pressure monitoring fails to address the acute risk during concurrent use; switching to methylphenidate without prescriber involvement violates controlled substance regulations and does not eliminate the interaction risk. A common misconception is that all stimulants are interchangeable without oversight, but Schedule II medications require prescriber authorization for changes. A transferable clinical pearl is to always check for MAOI interactions with sympathomimetic agents like stimulants using resources like drug interaction databases. Guidelines for controlled substance management emphasize proactive pharmacist intervention in potential interactions to prevent adverse events.

Question 15

1. Submit a MedWatch report because serious opioid-related adverse effects (confusion, severe constipation) can be reported to FDA, especially if unexpected or requiring intervention (correct answer)
2. Do not report because only medication errors (not adverse effects) are eligible for MedWatch
3. Report only to the DEA because adverse effects of Schedule II medications must be reported to DEA instead of FDA
4. Wait to report until the patient has been on oxycodone for at least 6 months to establish causality

Explanation: This question assesses the reporting of adverse events associated with controlled substances through appropriate channels. The key patient-specific factors are severe constipation and confusion from high-dose oxycodone post-surgery, which are serious and unexpected adverse effects requiring intervention. Option A is the best choice as submitting a MedWatch report to the FDA is appropriate for serious opioid-related events, facilitating post-marketing surveillance and safety improvements. Option B is incorrect because MedWatch accepts both errors and adverse effects, a misconception limiting its scope. Option C wrongly directs to DEA, which focuses on diversion, not adverse events; option D delays reporting unnecessarily, as causality can be assessed later. A pearl is that pharmacists are encouraged to report serious ADEs voluntarily via MedWatch for all drugs, including controlled substances. Use a framework evaluating event severity and unexpectedness to decide on reporting, enhancing pharmacovigilance in controlled substance management.

Question 16

1. Dispense as written and counsel only on opioid sedation because acetaminophen is safe at any dose if taken with food
2. Counsel to limit total daily acetaminophen from all sources (generally not exceeding 3,000–4,000 mg/day; consider lower in liver disease) and contact prescriber if dose adjustment is needed (correct answer)
3. Recommend adding an over-the-counter acetaminophen/diphenhydramine product at bedtime for sleep while using oxycodone/acetaminophen
4. Recommend taking 2 tablets every 4 hours scheduled for 30 days to prevent pain recurrence

Explanation: This question evaluates the prevention of acetaminophen toxicity in patients on opioid-acetaminophen combinations. The key patient-specific factors are the concurrent high-dose acetaminophen use and elevated liver enzymes from fatty liver disease, risking hepatotoxicity if total daily intake exceeds safe limits. Option B is the best choice as counseling to limit total acetaminophen to 3,000–4,000 mg/day (lower in liver disease) and contacting the prescriber if needed prevents overdose while ensuring pain control. Option A is incorrect because high acetaminophen doses are unsafe even with food, a misconception ignoring cumulative risk. Option C adds more acetaminophen; option D promotes excessive use. A pearl is that FDA limits acetaminophen in prescription products to 325 mg per unit. Use a framework calculating total daily acetaminophen from all sources in controlled substance counseling.

Question 17

1. Dispense pregabalin 150 mg twice daily as written because renal adjustment is not necessary
2. Contact the prescriber to recommend a reduced pregabalin dose due to renal impairment and counsel on additive sedation/respiratory depression risk with opioids (correct answer)
3. Recommend increasing oxycodone dose to offset pregabalin-related dizziness
4. Advise storing pregabalin in the freezer to maintain potency and prevent misuse

Explanation: This question assesses dose adjustments for pregabalin in renal impairment when combined with opioids. The key patient-specific factors are the reduced creatinine clearance of 28 mL/min and concurrent oxycodone, necessitating pregabalin dose reduction to avoid accumulation and additive sedation. Option B is the best choice as contacting the prescriber for adjustment and counseling on risks ensures safe use and prevents respiratory depression. Option A is incorrect because renal adjustment is required per labeling, a common oversight. Option C is suboptimal as increasing oxycodone worsens risks; option D provides improper storage advice. A clinical pearl is that pregabalin doses should be halved for CrCl <30 mL/min. Implement a decision framework calculating CrCl and screening for CNS depressant interactions in controlled substance prescribing.

Question 18

1. Advise her to continue phentermine and monitor blood pressure monthly because cardiovascular symptoms are expected early in therapy
2. Recommend tapering phentermine by decreasing to half a tablet daily for 2 weeks to prevent withdrawal before stopping
3. Recommend switching to amphetamine/dextroamphetamine (Schedule II) at an equivalent dose to maintain weight loss benefits
4. Advise discontinuation and urgent medical follow-up, and submit an FDA MedWatch report for a serious adverse event associated with phentermine (correct answer)

Explanation: This question evaluates the appropriate response to serious adverse events from controlled substances requiring regulatory reporting. The key patient-specific factors are serious cardiovascular events (chest pain, arrhythmia, near-syncope) occurring shortly after starting phentermine, a sympathomimetic anorectic with known cardiovascular risks. Option D is correct because it addresses both immediate patient safety (discontinuation and urgent follow-up) and regulatory requirements (FDA MedWatch reporting for serious adverse events). Option A is dangerous as it ignores serious cardiovascular toxicity that could progress to fatal outcomes. Option B incorrectly suggests tapering, which is unnecessary for phentermine and delays addressing the urgent safety issue. Option C inappropriately suggests switching to another stimulant which would likely cause similar or worse cardiovascular effects. The clinical framework emphasizes that serious adverse events from controlled substances require immediate discontinuation, appropriate medical referral, and regulatory reporting to FDA MedWatch to contribute to post-market surveillance and protect public health.

Question 19

1. Stop alprazolam immediately and start hydroxyzine 50 mg by mouth every 6 hours as needed to prevent withdrawal
2. Implement a gradual taper (for example, reduce total daily dose by about 10%–25% every 1–2 weeks) with close follow-up and patient-specific adjustments (correct answer)
3. Decrease alprazolam by 50% every 24 hours until discontinued to minimize total exposure
4. Continue the same alprazolam dose and monitor liver function tests monthly as the primary safety strategy

Explanation: This question evaluates benzodiazepine tapering strategies in a patient with long-term, high-dose use. The key patient-specific factors are 18 months of high-dose alprazolam use (6 mg daily), history of opioid use disorder, and no seizure history, making proper tapering essential to avoid withdrawal complications. Option B is correct because gradual tapering (10-25% dose reduction every 1-2 weeks) with individualized adjustments is the evidence-based approach for benzodiazepine discontinuation after long-term use. Option A is dangerous as abrupt cessation can cause severe withdrawal including seizures, and hydroxyzine cannot prevent benzodiazepine withdrawal. Option C suggests an overly aggressive taper that could precipitate withdrawal symptoms. Option D fails to address the patient's desire to discontinue and focuses on an irrelevant monitoring parameter. The clinical framework for benzodiazepine tapering emphasizes slow, gradual reduction with close monitoring for withdrawal symptoms, individualized pacing based on patient response, and potential use of adjunctive medications to manage symptoms rather than prevent withdrawal.

Question 20

1. Dispense as written because extended-release opioids are preferred for opioid-naïve patients to avoid peaks and troughs
2. Contact the prescriber to verify appropriateness and consider a lower dose/short-acting option; counsel on opioid risks and assess for contraindications before dispensing (correct answer)
3. Change the prescription to morphine immediate-release 60 mg every 8 hours without prescriber authorization
4. Recommend adding diazepam 10 mg three times daily to prevent opioid-induced anxiety

Explanation: This question evaluates the appropriateness of high-dose extended-release opioids in opioid-naïve patients. The key patient-specific factors are the patient's opioid-naïve status and high starting morphine dose of 180 mg/day equivalent, risking overdose without titration. Option B is the best choice as contacting the prescriber for verification, considering lower or short-acting options, and counseling on risks ensures safe initiation. Option A is incorrect because extended-release is not preferred for naïve patients per FDA, a misconception about formulation safety. Option C involves unauthorized changes; option D adds unnecessary benzodiazepine risk. A clinical pearl is that CDC recommends starting opioids at low doses (<50 MME/day) for chronic pain. Apply a framework calculating MME and assessing tolerance before dispensing long-acting controlled substances.